Rejection in Hla-Identical Living Related Donor Kidney Transplants

Burke, George W.; Allouch, Mustafa; Cirocco, Robert; Markou, M.; Gómez, Carmen; Contreras, Nancy; Esquenazi, Violet; Nery, Jose; Miller, Joshua

doi:10.1097/00007890-199403150-00021

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that acute rejection episodes (especially repeated ones) have an important negative effect on long‐term graft survival even in this population. This has been demonstrated by other investigators [14,23], with the exception of one report [24], and is probably due to smaller number of patients, shorter follow‐up period, and the absence of a distinction between single rejections versus multiple rejections in their analyses.…”

Section: Discussionmentioning

confidence: 71%

HLA‐identical sibling renal transplantation – a 21‐yr single‐center experience

Mattos

Bennett

Barry

et al. 1999

Clinical Transplantation

View full text Add to dashboard Cite

Human lymphocyte antigen (HLA)-identical sibling organs offer the best long-term outcomes for recipients of a renal transplant apart from an identical twin. Unlike cadaveric transplants, however, factors that affect long-term survival of these immunologically privileged grafts are not well described. We reviewed 108 HLA-identical transplants performed at our institution between January 1977 and February 1993. Variables chosen for graft survival analysis were: gender, age and ABO blood type of donors and recipients, panel reactivity antibodies (PRA), blood transfusions prior to transplant, pregnancies, and the underlying renal disease. Additionally, incidence of acute rejection (AR), timing of AR, serum creatinine levels at 1 wk and at 1 yr, and presence of hypertension were included in the analysis. Mean follow-up was 130.9 +/- 58.2 months (range 38-250 months). Actual 5-yr patient and graft survivals were 92 and 88%, respectively. Thirty-eight grafts were lost, and 22 recipients died during the observation period. Death was the main cause of graft failure. Cardiac events accounted for the majority of deaths. AR occurred in 46% and repeated rejections in 11% of recipients. Actuarial graft survival at 10 yr was poorer for patients with any AR (69%), and significantly worse with repeated AR (33%), compared to patients without AR (86%), p = 0.001). Sixty percent of all rejections and 88% of the first rejections occurred in the first 60 d post-transplantation. The first AR that occurred after 60 d was associated with poor graft survival (49 vs. 70%, p = 0.04). Recipients with renal diseases with potential to recur (membranous glomerulonephritis (MGN), membrano-proliferative glomerulonephritis (MPGN), focal and segmental glomerulonephritis (FSGN), polyarteritis nodosa (PAN), rapid progressive glomerulonephritis (RPGN), Henoch-Schoenlein purpura (HSP), diabetes mellitus (DM), interstitial nephritis, systemic lupus erythematosus (SLE) and chronic glomerulonephritis (CGN)) faired worse as a group than recipients with hypertensive nephrosclerosis (HTN), autosomal dominant polycystic kidney disease (ADPKD), Alport's, reflux or congenital dysplasia (68 vs. 96% at 10 yr, p = 0.0009). Poor patient survival was seen in diabetics (71 vs. 88% at 10 yr, p = 0.01). There was a trend to poorer graft survival in diabetic recipients when compared to non-diabetics (65 vs. 81% at 10 yr, p = 0.054). Elevated creatinine at 1 yr was associated with worse graft survival. Likewise, the magnitude of creatinine increase during the first year directly correlated with the risk of graft loss. Hypertensive patients were more likely to lose their grafts than normotensive recipients (72 vs. 86%, p = 0.04). Pre-transplant blood transfusion, pregnancy, and PRA level were not associated with increased graft failure or AR. Graft survival was not affected by gender, age, or ABO blood type of donors or recipients. In conclusion, better prevention and treatment of AR, hypertension, and cardiac disease should improve graft and patient survival. Close atten...

show abstract

Section: Discussionmentioning

confidence: 71%

HLA‐identical sibling renal transplantation – a 21‐yr single‐center experience

Mattos

Bennett

Barry

et al. 1999

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…In a large retrospective cohort study of major histocompatibility antigen–identical siblings, however, the presence of PRA in renal transplantation led to higher rates of late graft failure, 6 suggesting a role for non–major histocompatibility antigen systems—so‐called minor histocompatibility antigens. This could explain why transplants between subjects sharing the six major histocompatibility antigens may lead to rejection in 10 to 42 percent of cases 7,8 . Characterizing minor histocompatibility antigens is therefore of importance.…”

mentioning

confidence: 99%

Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection?

Lerut

Damme²,

Emonds³

et al. 2006

Transfusion

View full text Add to dashboard Cite

show abstract

“…Immune responses against non-HLA targets leading to transplant rejection and graft loss have been postulated following the rejection of kidneys from HLA identical sibling donors. [3][4][5][6][7] Polymorphic areas residing outside the HLA region, as well as nonpolymorphic antigens, were shown to correlate with reduced allograft survival in recent genetic studies. [8][9][10][11][12][13][14][15][16][17][18] The identification of these potential targets led to the development of technologies to detect non-HLA antibodies.…”

Section: The Role Of Non-hla Antibody Testing In Solid Organ Transpla...mentioning

confidence: 99%